Content area

|
|

Intravitreal angiostatisk behandling af okulær sygdom

Forfatter(e)
Lou-Ann Christensen Andersen1, Lasse Jørgensen Cehofski1, 2, 3 & Jakob Grauslund1, 3, 4
1) Øjenafdelingen, Odense Universitetshospital 2) Øjenafdelingen, Vejle Sygehus – Sygehus Lillebælt 3) Klinisk Institut, Syddansk Universitet 4) Steno Diabetes Center Odense

Ugeskr Læger 2019;181:V04190256

Reference: 
Ugeskr Læger 2019;181:V04190256

Lou-Ann Christensen Andersen, Lasse Jørgensen Cehofski & Jakob Grauslund:

Intravitreal angiostatic treatment of ocular vascular diseases

Ugeskr Læger 2019;181:V04190256

Intraocular vascular diseases like neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion are associated with decline in vision if left untreated. Anti-vascular endothelia growth factor (VEGF) agents originally developed for cancer treatment were the beginning of a new treatment regime for intraocular vascular diseases. Ambiguous results exist regarding adverse effects but are considered limited. In the future, anti-VEGF agents are likely to be used for treatment of proliferative diabetic retinopathy, neovascular glaucoma and premature retinopathy.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Hanne Pedersen | 17/11
1 Kommentar
af Mads Aage Toft Kristensen | 16/11
1 Kommentar
af Ketil Bjerregård | 15/11
1 Kommentar
af Jens Lund Ahrenkiel | 15/11
1 Kommentar
af Nicolaj Markus Stilling | 15/11
2 kommentarer
af Marianne Puge Nielsen | 13/11
1 Kommentar
af Akil Raad Kami Abdel-Wahab Walli | 13/11
6 kommentarer
af Larry Højgaard Kristiansen | 11/11
1 Kommentar